Nonalcoholic steatohepatitis (NASH) is an increasingly common cause of chronic liver disease worldwide. Currently, no specific pharmacologic therapy has been shown to treat NASH effectively. Because ...

Pioglitazone (Matce -P 30) is a thiazolidinedione antidiabetic, prescribed for type 2 diabetes in certain patients. It is used along with diet and exercise. It may be used alone or with other ...

Pioglitazone is a thiazolidinedione antidiabetic, prescribed for type 2 diabetes in certain patients. It is used along with diet and exercise. It may be used alone or with other antidiabetic medicines ...

Objective: Hepatic triglyceride is closely associated with hepatic insulin resistance and is known to be decreased by thiazolididinediones. We studied the effect of pioglitazone on hepatic ...

In a new, proof-of-concept study, pioglitazone has been shown to lessen the metabolic and histologic abnormalities associated with nonalcoholic steatohepatitis (NASH), for which there is currently no ...

BOSTON, April 30, 2004 – Results of three studies show the oral anti-diabetic agent ACTOS (R) (pioglitazone HCl), in combination with a sulfonylurea, metformin or insulin, resulted in triglyceride ...

Women with polycystic ovary syndrome (PCOS) tend to be overweight and insulin-resistant, but pioglitazone treatment improves their insulin sensitivity, and leads to improved ovulatory function. High ...

Actos (pioglitazone) is a prescription drug that’s used to treat type 2 diabetes. The drug comes as an oral tablet that’s taken once per day. Actos is used to help manage blood sugar levels in adults ...

The FDA has released an updated safety announcement following a fresh review of data on the type 2 diabetes treatment pioglitazon to confirm that the drug may increase a person’s likelihood of ...

Orlando FL, June 5, 2004 – Type 2 diabetes and hypertension are commonly associated conditions, both of which carry an increased risk of cardiovascular disease. Results of a large, open-label, ...

Please provide your email address to receive an email when new articles are posted on . Patients with type 2 diabetes may have another therapeutic option to improve vascular dysfunction and markers of ...